James
One of the major actions of insulin that becomes defective in type 2 diabetes is the regulated entry of nutrients into our muscle and fat cells. Our goal is to use our newly-developed molecular imaging methods to uncover the path that insulin takes from when it binds to muscle and fat cells to when it encounters its final target, and how it achieves its ultimate goal: allowing glucose to gain entry to a cell. Numerous proteins interact with insulin and glucose on this journey. We are also intrigued by the constant movement of proteins within cells, the direction and rate of which is precisely controlled and are investigating the mechanism for the regulation of protein trafficking.
Staff
Dr Jacqueline Stoeckli |
|
Dr Georg Ramm |
Dr Kyle Hoehn |
Dr Ping Zhao |
|
Poh Sim Khoo |
|
| PhD Student Mark Larance |
PhD Student Jamie Lopez |
Samantha Hocking |
Jonathan Davey |
Alex Rowland |
Yvonne Ng |
Lindsay Wu |
Freddy Yip |
News
Research agreement to reveal secret lives of cells
MEDIA RELEASE:
06 Aug 2008
Garvan and CSIRO have signed a three-year collaboration agreement to investigate important cellular processes, including those impaired by diseases such as diabetes. They will be using a new computer vision system they developed jointly to watch intricate cellular processes in real time.
A tonne of bitter melon produces sweet results for diabetes
MEDIA RELEASE:
22 Mar 2008
Teams from the Garvan Institute of Medical Research and the Shanghai Institute of Materia Medica pulped roughly a tonne of fresh bitter melon and extracted four very promising bioactive components that explain why it is has been used in Chinese medicine for hundreds of years. It now promises to be an effective treatment for Type 2 diabetes.
New Fellowship Strengthens Garvan Potential to find a cure for Type 2 diabetes
MEDIA RELEASE:
06 Dec 2007
We are very pleased to announce the establishment of the GlaxoSmithKline Don Chisholm Fellowship for Diabetes Research – a position dedicated to vital research into the causes, processes and treatments for Type 2 diabetes, one of Australia’s most common and serious diseases.
